Study shows efficacy of anti-VEGF therapy in myopic CNV
Based on positive outcomes from the RADIANCE trial, ranibizumab has recently been approved by European authorities as a treatment for patients with choroidal neovascularization (CNV) secondary to pathologic myopia, according to Sebastian Wolf MD.
“The trial data showed that ranibizumab provides rapid and superior improvement in visual acuity compared with the current licensed standard of care, photodynamic therapy with verteporfin after three months. There was an average 14-letter visual acuity gain in the first year with a median of two injections and more than 60 per cent of patients in the study did not need any further injections after six months,” said Dr Wolf.
Tags: intraocular pressure
Latest Articles
Addressing Postoperative Visual Complications
Managing aberrations after laser refractive surgery requires a multi-layered approach.
3D Printing Helps Transform Ukrainian Eye Care
The country’s ophthalmologists offer valuable experience in treating ocular trauma and prosthesis design.
Winning Essay Says ‘Collective Desire’ Must Drive DEI Implementation
Emerging Microbial Trends That Could Affect Your Practices
A triptych of challenges paints a concerning picture for ophthalmologists across the globe.
Improving Outcomes with Laser-Assisted Surgery
Femtosecond laser offers a multifunctional tool for improving the safety and efficacy of cataract and refractive lens exchange procedures.
Could the Corneal Transplant Pool Increase?
Modifying or discarding major contraindications for keratoplasty could mean more patients have their sight restored.
Matching Premium IOLs to Visual Lifestyles
From monofocal to full-range solutions, each practice needs comprehensive understanding.
Going Dutch on Acanthamoeba Keratitis
A world-first trial suggests a new medication could beat the disease.
Avoiding Intracorneal Ring Segment Complications
Femtosecond lasers are helping improve refractive results with fewer problems.